Rhenman & Partners Asset Management AB recently filed their 13F report for the first quarter of 2022, which ended on 2022-03-31.
The 13F report details which stocks were in a guru’s equity portfolio at the end of the quarter, though investors should note that these filings are limited in scope, containing only a snapshot of long positions in U.S.-listed stocks and American depository receipts as of the quarter’s end. They are not required to include international holdings, short positions or other types of investments. Still, even this limited filing can provide valuable information.
Strandvagen 5a Stockholm, V7 11451
As of the latest 13F report, the guru’s equity portfolio contained 90 stocks valued at a total of $1,014,000,000. The top holdings were HZNP(3.49%), LLY(3.49%), and ABBV(3.12%).
According to GuruFocus data, these were Rhenman & Partners Asset Management AB’s top five trades of the quarter.
UnitedHealth Group Inc
Rhenman & Partners Asset Management AB reduced their investment in NYSE:UNH by 62,000 shares. The trade had a 2.08% impact on the equity portfolio. During the quarter, the stock traded for an average price of $481.86.
On 05/16/2022, UnitedHealth Group Inc traded for a price of $485.4 per share and a market cap of $455,388,496,000. The stock has returned 20.23% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 9 out of 10.
In terms of valuation, UnitedHealth Group Inc has a price-earnings ratio of 26.57, a price-book ratio of 6.26, a price-earnings-to-growth (PEG) ratio of 2.01, a EV-to-Ebitda ratio of 17.37 and a price-sales ratio of 1.57.
The price-to-GF Value ratio is 1.21, earning the stock a GF Value rank of 3.
Regeneron Pharmaceuticals Inc
The guru established a new position worth 28,500 shares in NAS:REGN, giving the stock a 1.96% weight in the equity portfolio. Shares traded for an average price of $632.11 during the quarter.
On 05/16/2022, Regeneron Pharmaceuticals Inc traded for a price of $645.52 per share and a market cap of $70,907,915,000. The stock has returned 24.82% over the past year.
GuruFocus gives the company a financial strength rating of 9 out of 10 and a profitability rating of 10 out of 10.
In terms of valuation, Regeneron Pharmaceuticals Inc has a price-earnings ratio of 9.14, a price-book ratio of 3.56, a price-earnings-to-growth (PEG) ratio of 0.23, a EV-to-Ebitda ratio of 7.02 and a price-sales ratio of 4.40.
The price-to-GF Value ratio is 0.66, earning the stock a GF Value rank of 8.
Pfizer Inc
Rhenman & Partners Asset Management AB reduced their investment in NYSE:PFE by 477,500 shares. The trade had a 1.85% impact on the equity portfolio. During the quarter, the stock traded for an average price of $51.88.
On 05/16/2022, Pfizer Inc traded for a price of $49.92 per share and a market cap of $280,095,918,000. The stock has returned 28.43% over the past year.
GuruFocus gives the company a financial strength rating of 7 out of 10 and a profitability rating of 8 out of 10.
In terms of valuation, Pfizer Inc has a price-earnings ratio of 11.45, a price-book ratio of 3.63, a price-earnings-to-growth (PEG) ratio of 1.09, a EV-to-Ebitda ratio of 8.47 and a price-sales ratio of 3.10.
The price-to-GF Value ratio is 0.62, earning the stock a GF Value rank of 4.
Anthem Inc
Rhenman & Partners Asset Management AB reduced their investment in NYSE:ANTM by 51,801 shares. The trade had a 1.61% impact on the equity portfolio. During the quarter, the stock traded for an average price of $456.86.
On 05/16/2022, Anthem Inc traded for a price of $486.45 per share and a market cap of $117,275,691,000. The stock has returned 24.19% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 9 out of 10.
In terms of valuation, Anthem Inc has a price-earnings ratio of 19.15, a price-book ratio of 3.26, a price-earnings-to-growth (PEG) ratio of 1.50, a EV-to-Ebitda ratio of 13.10 and a price-sales ratio of 0.83.
The price-to-GF Value ratio is 1.11, earning the stock a GF Value rank of 5.
Biogen Inc
Rhenman & Partners Asset Management AB reduced their investment in NAS:BIIB by 100,000 shares. The trade had a 1.6% impact on the equity portfolio. During the quarter, the stock traded for an average price of $217.68.
On 05/16/2022, Biogen Inc traded for a price of $199.11 per share and a market cap of $29,160,060,000. The stock has returned -29.32% over the past year.
GuruFocus gives the company a financial strength rating of 6 out of 10 and a profitability rating of 9 out of 10.
In terms of valuation, Biogen Inc has a price-earnings ratio of 20.38, a price-book ratio of 2.61, a EV-to-Ebitda ratio of 11.39 and a price-sales ratio of 2.73.
The price-to-GF Value ratio is 0.82, earning the stock a GF Value rank of 10.
Please note, the numbers and facts quoted are as of the writing of this article and may not factor in the latest trading data or company announcements.
Want to provide feedback on this article? Have questions or concerns? Get in touch with us here, or email us at [email protected]!
This article is general in nature and does not represent the opinions of GuruFocus or any of its affiliates. This article is not intended to be financial advice, nor does it constitute investment advice or recommendations. It was written without regard to your individual situation or financial goals. We aim to bring you fundamental, data-driven analysis, The information on this site is in no way guaranteed for completeness, accuracy or in any other way.
